Uveitisinduktion durch immunonkologische Therapien, speziell Checkpoint-Inhibitoren

Zusammenfassung

Hintergrund Immun-Checkpoint- und BRAF-/MEK-Inhibitoren (ICI) haben eine zentrale Stellung in der Krebstherapie eingenommen, da sie eine erhebliche Lebensverlängerung bei einer guten Verträglichkeit und Lebensqualität bewirken. Sie sind jedoch mit stoffklassenspezifischen, nicht toxischen immunologischen Nebenwirkungen, darunter auch Entstehung einer Uveitis, behaftet. In dieser Übersicht soll der aktuelle Kenntnisstand zu Wirkprinzip und systemischen und okulären Nebenwirkungen der ICI dargestellt werden.

Methoden Dieser Übersicht liegt eine Literatursuche in PubMed, der Datenbank des National Institute of Health der USA (https://www.ncbi.nlm.nih.gov/pubmed) mit den Stichworten „uveitis“ AND „drug-induced“ AND/OR „immune checkpoint inhibitor“ zugrunde. Alle relevant erscheinenden Publikationen der letzten 5 Jahre wurden zusammen mit den darin zitierten Querverweisen ausgewertet.

Ergebnisse Ein klassenspezifisches Phänomen der sonst gut verträglichen ICI ist ihre Fähigkeit, eine systemische und okuläre Autoimmunität auszulösen. Diese unterscheidet sich von toxischen Nebenwirkungen durch ihre Dosisunabhängigkeit. Okuläre Nebenwirkungen treten bei 3% der Patienten auf, wobei ein Melanom als Grunderkrankung und eine Therapie mit Pembrolizumab das Risiko um ein Mehrfaches erhöhen. Eine frühe Diagnose und systemische Steroidtherapie dieser potenziell lebensbedrohlichen Nebenwirkung erlauben in > 90% die Erhaltung der Sehfunktion und Lebensqualität, ohne die ICI-Therapie abzusetzen.

Schlussfolgerung Das therapeutische Ansprechen von Malignomen auf ICI bezüglich des Überlebens und der Verträglichkeit, insbesondere bei Melanomen, lässt eine zunehmende Anwendung von ICI auch in Therapiekombinationen und damit eine Zunahme der immunologischen Komplikationen im klinischen Alltag erwarten. In Anbetracht einer Mortalität von unbehandelt bis zu 3% infolge immunvermittelter Nebenwirkungen an multiplen Organen ist eine rasche interdisziplinäre Abklärung und rechtzeitige aggressive Behandlung zwingend, führt aber meist auch zu erfreulichen funktionellen Ergebnissen.

Abstract

Background The recently introduced tumor therapies including immune checkpoint and BRAF/MEK inhibitors (ICI) have substantially contributed to survival and quality of life of the affected patients, but are associated with class-specific, non-toxic immune-related side effects including uveitis. This narrative review focusses to summarize the immune-related adverse event profile associated with the use of ICI.

Methods A literature search in PubMed, the publication database of the National Institute of Health in the USA (https://www.ncbi.nlm.nih.gov/pubmed) used the search terms “uveitis” AND “drug-induced” AND/OR “immune checkpoint inhibitor”. All articles published in the last five years and the for the purpose of this review relevant cross references were evaluated.

Results A class-specific phenomenon of ICI and BRAF/MEK inhibitors is their capability to induce systemic and ocular autoimmunity. Ocular side effects are observed in up to 3% of patients and should be differentiated from toxic side effects, since this is not dose-dependent. Melanoma as underlying disease and Pembrolizumab as ICI significantly increase the risk. If timely recognized, systemic treatment with corticosteroids allows to preserve vision without cessation of the tumor treatment in more than 90% of these potentially life-threatening instances.

Conclusion Given their impact onto the survival of cancer and namely melanoma patients, ICI and BRAF/MEK inhibitors are increasingly used alone and in combination, which enhances their inherent risk of developing drug-induced ocular autoimmunity. Favorable functional outcomes are closely linked to early recognition and aggressive treatment of these complications considering the fact that these immune-related adverse events affect multiple organ systems and have an untreated lethality of up to 3%.

Schlüsselwörter

Immun-Checkpoint-Inhibitor - BRAF-/MEK-Inhibitor - Uveitis - Pembrolizumab - nicht toxische Nebenwirkung - medikamentös induzierte Autoimmunerkrankung

Key words

immune checkpoint inhibitor - BRAF/MEK inhibitor - uveitis - anti-PD1/anti-PD-L1 antibody - immune-related adverse event - drug-induced autoimmunity

Publication History

Received: 21 September 2021

Accepted: 06 February 2022

Article published online:
26 April 2022

• Literatur

• 1 Moorthy RS, Moorthy MS, Cunningham jr. ET. Drug-induced uveitis. Curr Opin Ophthalmol 2018; 29: 588-603 DOI: 10.1097/ICU.0000000000000530.
• 2 Cordero-Coma M, Salazar-Méndez R, Garzo-García I. et al. Drug-induced uveitis. Expert Opin Drug Saf 2015; 14: 111-126 DOI: 10.1517/14740338.2015.972363.
• 3 Anquetil C, Salem JE, Lebrun-Vignes B. et al. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHOʼs pharmacovigilance database. J Autoimmun 2020; 111: 102454 DOI: 10.1016/j.jaut.2020.102454.
• 4 Samalia P, Sims J, Niederer R. Drug-induced ocular inflammation. N Z Med J 2020; 133: 83-94
• 5 Liu CY, Francis JH, Brodie SE. et al. Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina 2014; 34: 1261-1280 DOI: 10.1097/IAE.0000000000000242.
• 6 Jain KK. Personalized Immuno-Oncology. Med Princ Pract 2021; 30: 1-16 DOI: 10.1159/000511107.
• 7 Kim K, Khang D. Past, Present, and Future of Anticancer Nanomedicine. Int J Nanomedicine 2020; 15: 5719-5743
• 8 Martins F, Sofiya L, Sykiotis GP. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16: 563-580 DOI: 10.1038/s41571-019-0218-0.
• 9 Ferrara R, Imbimbo M, Malouf R. et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database Syst Rev 2021; (04) CD013257 DOI: 10.1002/14651858.CD013257.pub3.
• 10 Knox MC, Ni J, Bece A. et al. A Clinicianʼs Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications. Front Immunol 2020; 11: 1612
• 11 Fan Y, Geng Y, Shen L. et al. Advances on immune-related adverse events associated with immune checkpoint inhibitors. Front Med 2021; 15: 33-42 DOI: 10.1007/s11684-019-0735-3.
• 12 Dalvin LA. et al. Checkpoint Inhibitor Immune Therapy: Systemic Indications and Ophthalmic Side Effects. Retina 2018; 38: 1063-1078
• 13 Kadono T. Immune-related adverse events by immune checkpoint inhibitors. Nihon Rinsho Meneki Gakkai Kaishi 2017; 40: 83-89 DOI: 10.2177/jsci.40.83.
• 14 Balibegloo M, Nejadghaderi SA, Sadeghalvad M. et al. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis. Int Immunopharmacol 2021; 96: 107796 DOI: 10.1016/j.intimp.2021.107796.
• 15 Rapisuwon S, Izar B, Batenchuk C. et al. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. J Immunother Cancer 2019; 7: 61 DOI: 10.1186/s40425-019-0533-0.
• 16 Komiya K, Nakamura T, Abe T. et al. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer 2019; 10: 1798-1804 DOI: 10.1111/1759-7714.13149.
• 17 Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195-201 DOI: 10.1016/j.it.2006.02.001.
• 18 Zhang S, Zhou Z, Wang L. et al. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Ther Adv Chronic Dis 2021; 12: 2040622320976996 DOI: 10.1177/2040622320976996.
• 19 Berti A, Bortolotti R, Dipasquale M. et al. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. Crit Rev Oncol Hematol 2021; 162: 103351 DOI: 10.1016/j.critrevonc.2021.103351.
• 20 Lidar M, Giat E, Garelick D. et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 2018; 17: 284-289 DOI: 10.1016/j.autrev.2018.01.003.
• 21 Wildner G. Tumors, tumor therapies, autoimmunity and the eye. Autoimmun Rev 2021; 20: 102892 DOI: 10.1016/j.autrev.2021.102892.
• 22 Alba-Linero C, Alba E. Ocular side effects of checkpoint inhibitors. Surv Ophthalmol 2021; 66: 951-959 DOI: 10.1016/j.survophthal.2021.01.001.
• 23 Bomze D, Meirson T, Hasan Ali O. et al. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. Ocul Immunol Inflamm 2020; DOI: 10.1080/09273948.2020.1773867.
• 24 Kim ST, Pundole X, Dadu R. et al. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. Immunotherapy 2021; 13: 465-475 DOI: 10.2217/imt-2020-0272.
• 25 Halle BR, Betof Warner A, Zaman FY. et al. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother Cancer 2021; 9: e003066 DOI: 10.1136/jitc-2021-003066.
• 26 Alexander S, Swami U, Kaur A. et al. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Ann Transl Med 2021; 9: 1033 DOI: 10.21037/atm-20-8124.
• 27 Dow ER, Yung M, Tsui E. Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes. Ocul Immunol Inflamm 2021; 29: 203-211 DOI: 10.1080/09273948.2020.1781902.
• 28 Noble CW, Gangaputra SS, Thompson IA. et al. Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. Ocul Immunol Inflamm 2020; 28: 854-859 DOI: 10.1080/09273948.2019.1583347.
• 29 Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 2007; 25: 613-631 DOI: 10.1080/07357900701522315.
• 30 Sun MM, Levinson RD, Filipowicz A. et al. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocul Immunol Inflamm 2020; 28: 217-227 DOI: 10.1080/09273948.2019.1577978.
• 31 Fang T, Maberley DA, Etminan M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol 2019; 31: 319-322 DOI: 10.1016/j.joco.2019.05.002.
• 32 Abdel-Rahman O, Oweira H, Petrausch U. et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther 2017; 17: 387-394
• 33 Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol 2016; 28: 288-294 DOI: 10.1097/CCO.0000000000000296.
• 34 Dimitriou F, Urner-Bloch U, Eggenschwiler C. et al. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. Eur J Cancer 2021; 144: 215-223 DOI: 10.1016/j.ejca.2020.11.027.
• 35 Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol 2021; 105: 1263-1271 DOI: 10.1136/bjophthalmol-2020-316970.
• 36 Xia T, Brucker AJ, McGeehan B. et al. Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database. Br J Ophthalmol 2022; 106: 87-90 DOI: 10.1136/bjophthalmol-2020-317060.
• 37 Kim YJ, Lee JS, Lee J. et al. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. Cancer Immunol Immunother 2020; 69: 2441-2452 DOI: 10.1007/s00262-020-02635-3.
• 38 Thurau S, Engelke H, McCluskey P. et al. Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-Inhibitors. Ocul Immunol Inflamm 2021; DOI: 10.1080/09273948.2021.1910850.
• 39 Zhang H, Li X, Huang X. et al. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. J Clin Pharm Ther 2021; 46: 927-935 DOI: 10.1111/jcpt.13469.
• 40 Li M, Wong D, Vogel AS. et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology 2022; 75: 531-540 DOI: 10.1002/hep.32215.
• 41 Johns AC, Wei L, Grogan M. et al. Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. J Geriatr Oncol 2021; 12: 813-819 DOI: 10.1016/j.jgo.2021.02.002.
• 42 El Hazzaz R, Kfoury M, Lavaud P. et al. [Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors]. Bull Cancer 2021; 108: 635-642 DOI: 10.1016/j.bulcan.2021.01.015.
• 43 Tyan K, Baginska J, Brainard M. et al. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother 2021; 70: 2209-2221 DOI: 10.1007/s00262-021-02855-1.
• 44 Gonugunta AS, von Itzstein MS, Mu-Mosley H. et al. Humoral and cellular correlates of a novel immune-related adverse event and its treatment. J Immunother Cancer 2021; 9: e003585 DOI: 10.1136/jitc-2021-003585.
• 45 Coschi CH, Juergens RA. The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. Curr Oncol 2021; 28: 4392-4407 DOI: 10.3390/curroncol28060373.
• 46 Alvarez M, Otano I, Minute L. et al. Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity. Cell Stress 2019; 3: 236-239 DOI: 10.15698/cst2019.07.193.
• 47 DʼSouza M, Bagger M, Alberti M. et al. Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancer-A Nationwide Cohort Study. Cancers (Basel) 2021; 14: 49 DOI: 10.3390/cancers14010049.
• 48 Conrady CD, Larochelle M, Pecen P. et al. Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol 2018; 256: 187-191 DOI: 10.1007/s00417-017-3835-2.
• 49 Telfah M, Whittaker TJ, Doolittle GC. Vision loss with pembrolizumab treatment: A report of two cases. J Oncol Pharm Pract 2019; 25: 1540-1546 DOI: 10.1177/1078155219841683.